It is currently believed that the risks of long-term use of HRT outweigh the benefits overall. HRT should not be recommended for disease prevention, except for women under the age of 60 with a significantly increased risk of bone fractures or associated with premature menopause. Women over the age of 50 who have been using combined estrogen and progestin substitutes for less than five years have little or no increased risk of breast cancer. Women who use the combined HRT for more than five years have a slightly higher risk.
Sometimes the amount of hormones a woman takes is adjusted based on blood tests of hormone levels. Marketers often describe bioidentical hormones as “natural,” and buyers often think they’re safer than other forms of estrogen and progestin used to control menopausal symptoms. So far, however, there are no long-term studies on bioidentical hormones, and no studies have found that women who take bioidentical hormones have fewer serious side effects than women who take other forms of these hormones. For this reason, bioidentical hormones can be assumed to have the same health risks as any other type of hormone therapy.
The effects of postmenopausal hormone therapy on social activity, relationship and sex life: experiences of the EPHT study. For example, for certain types of breast cancer, people can take hormone therapy daily for 5 to 10 years. This means that they receive hormone therapy at certain times, but treatment is temporarily stopped before it starts again. After thyroid cancer treatment, hormone therapy is often a daily part of a person’s life.
Menopausal symptoms can be treated with education, lifestyle changes, support, and hormone replacement therapy, also known as hormone therapy during menopause. Recent findings show that HRT, while not completely risk-free, remains the most effective solution for treating menopausal symptoms and is also effective for preventing osteoporosis. Estrogen and progesterone are female hormones that play an important role in a woman’s body. Declining levels cause a variety of physical and emotional symptoms, including hot flashes, mood swings, and vaginal dryness. Some women have unpleasant symptoms such as hot flashes and vaginal dryness.
Other studies have found a link between systemic pure estrogen HRT and an increased risk of ovarian cancer. The re-analysis of GHI data by age cohort showed that the risks of breast cancer, stroke and heart disease did not increase in the fifth decade, but increased in the sixth and seventh decades. The risk of breast cancer was evident in women who were exposed to high blood pressure before entering the GHI study after a washout phase, but not in those who had never received HT. HRT first became available in the 1940s, but became more widespread in the 1960s, leading to a revolution in menopause management. It is advisable for women with a history of breast cancer to avoid HRT unless other treatments are ineffective and their quality of life becomes unbearable due to menopausal symptoms.
Some researchers reported an increased risk of using estrogen, while others reported no effect or protective effect. This confusion of results has been attributed to the fact that ovarian cancer is a rare disease and that the number of patients in studies that have tried to elucidate the relationship has been insufficient. There is no evidence that a woman with a family history of breast cancer HRT For Me has an additional increased risk of developing breast cancer when she uses HRT. The risk with the combination of estrogen and progestin is higher than with estrogen alone or with newer HRT agents such as tibolone and may also depend on the type of progestin used. Studies suggest that medroxyprogesterone acetate and norethisterone have higher risks than dydrogesterone and progesterone.
In these circumstances, HRT should be prescribed to the woman only in consultation with the breast surgeon or oncologist. Literally hundreds of clinical trials have provided evidence that systemic HT effectively supports conditions such as hot flashes, vaginal dryness, night sweats, and bone loss. These benefits can lead to improved sleep, intercourse, and quality of life. Because of this increased risk of cancer, women who have gone through menopause and still have a uterus are given progestin along with estrogen. Studies have shown that EFA does not increase the risk of endometrial cancer.
Studies from the Women’s Health Initiative also found no increased risk of breast cancer in women who use systemic HRT with estrogen alone. Years ago, before the link between HRT use and breast cancer risk became known, many women took HRT for years to relieve menopausal symptoms and prevent bone loss. After 2002, when research linked HRT and breast cancer risk, the number of women taking HRT dropped dramatically.